Meet ACELYRIN
Building a Different Kind of Biopharma Company
For Media and Investor Inquiries, contact:
Tyler Marciniak,
Vice President of Investor Relations,
Communications and Corporate Operations
Media Kit
Explore our site
Meet Our Leadership
We are led by experienced biopharma executives with exceptional track records of building strong, innovative and diverse teams across the healthcare industry.
Meet our leadership
See Our Pipeline
We are exploring innovative approaches in immunology where we have the opportunity to make a clinically meaningful difference for patients.
See our pipelineIzokibep - Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis 
Publication
Izokibep - Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis
Read more ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
Press Release
ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
Read more